The dataset viewer is not available because its heuristics could not detect any supported data files. You can try uploading some data files, or configuring the data files location manually.
YAML Metadata Warning:empty or missing yaml metadata in repo card
Check out the documentation for more information.
ACE2-B0AT1 🎉 New Dataset Release: Novel Ligand Designs for ACE2-B0AT1
I'm excited to share that a new dataset of novel ligand designs targeting the ACE2-B0AT1 complex has been uploaded and is now publicly available. This target is generating significant excitement in the research community, particularly after the recent positive Phase I clinical trial results from MAZE Therapeutics for their SLC6A19 (the gene for B0AT1) inhibitor, MZE782
.
You can directly access and download the dataset here: 👉 https://huggingface.co/datasets/Tc-43/ACE2-B0AT1 Why the ACE2-B0AT1 Target Matters
The ACE2-B0AT1 complex is a critical heterodimer for neutral amino acid absorption in the intestines and kidneys . It has gained attention not only for its role in metabolic disorders like Hartnup disease but also as a receptor for SARS-CoV-2
.
The biology is fascinating: B0AT1 requires a partner—ACE2 in the gut and collectrin in the kidney—to reach the cell surface and function
. This tissue-specific partnership is key to understanding its mechanism and therapeutic potential. The Clinical Connection: MAZE Therapeutics' Breakthrough
The buzz around this target is well-founded. In September 2025, Maze Therapeutics announced positive first-in-human results for MZE782, an oral SLC6A19 inhibitor
.
The Phase I data was compelling
:
Proof of Mechanism: The drug showed a dose-dependent, massive increase (up to a 42-fold rise) in urinary phenylalanine excretion, confirming potent target engagement.
Therapeutic Potential: MZE782 is being developed as a potential best-in-class therapy for Phenylketonuria (PKU) and a first-in-class treatment for Chronic Kidney Disease (CKD).
Safety: It demonstrated an excellent safety profile in healthy volunteers, supported by the generally benign nature of Hartnup disorder, which also involves reduced SLC6A19 function
.
About the Dataset
This resource provides computational chemists, structural biologists, and drug discovery researchers with a set of novel ligand designs to explore. Investigating these ligands could accelerate the development of new therapeutics for kidney and metabolic diseases by targeting this pivotal pathway.
Download, experiment, and let me know what you discover! I'd love to hear your thoughts and feedback.
- Downloads last month
- 5